Readoutin 13d
Adverum Biotechnologies, Inc. — Ixo-vec
Phase 3 primary completion: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Neovascular Age-Related Macular Degeneration (nAMD)